infarction (AMI), our assay can detect and quantify concentrations of protein biomarkers, like troponin, to diagnose AMI in under two minutes with high precision. This rapid, cost-effective, and highly accurate test will enable EMTs, paramedics and emergency department staff to quickly diagnose AMI and initiate critical interventions, saving lives and drastically reducing healthcare costs. We’re initially targeting the $5.9 billion high-sensitivity cardiac troponin assay market and expanding to other indications in the $15 billion rapid acute care diagnostic market with broader applications in the $62.3 billion global point-of-care diagnostic market. We secured significant seed funding, including over $2 million in NSF and NIH Phase I and II SBIR grants, have strong licensing interest from several of the top diagnostics companies, and are currently looking for partners and investors for our $10 million Series A round to join us in revolutionizing point-of-care diagnostics.